Updated 12-12-24 to reflect the chance in name from Epic Bio to Epicrispr Biotechnologies. Leading-edge CRISPR biotech chooses FSHD as its first disease target Epicrispr Biotechnologies, based in the San… Read More »
Epic Bio takes aim at DUX4
Roche announces Phase 2 trial in FSHD
The drug, GYM329, aims to boost muscle growth Roche, the Swiss pharmaceutical giant, has announced that it is launching an international Phase 2 clinical trial for facioscapulohumeral muscular dystrophy (FSHD)…. Read More »
Sanofi and miRecule to partner on FSHD drug program
Bringing two technologies together for a best-in-class therapy miRecule, Inc., a biotech based in Gaithersburg, Maryland, today announced a strategic collaboration and exclusive license agreement with pharmaceutical giant Sanofi to… Read More »
SOLVE FSHD Invests US $1 Million in miRecule
Funds aim to accelerate development of best-in-class antibody-RNA conjugate to treat facioscapulohumeral muscular dystrophy GAITHERSBURG, Maryland and VANCOUVER, British Columbia – September 29, 2022 (View original source.) – miRecule, Inc.,… Read More »
Avidity Biosciences announces Phase 1/2 trial for FSHD
Trial has FDA approval. Start dates and locations have not yet been determined. Update as of 11/21/2024: AOC 1020 is now being referred to as Del-brax. San Diego-based Avidity Biosciences… Read More »